AppLovin Stock Soars After Big Q1 Earnings Beat and Strong Q2 Outlook
AppLovin beat Q1 earnings, raised outlook, and grew revenue with strong AI-driven ads, boosting stock.
Already have an account? Sign in.
AppLovin beat Q1 earnings, raised outlook, and grew revenue with strong AI-driven ads, boosting stock.
BMO Capital gives Trevi Therapeutics an Outperform rating and $36 target, citing strong potential for Haduvio as a first-in-class treatment for chronic cough in idiopathic pulmonary fibrosis.
Analyst forecasts show Intel and Samsung struggling to close the gap on A16 and N2 technology.
Genuine Parts lowered its 2026 profit outlook amid weaker consumer demand. CEO Will Stengel denied rumors of a rival acquiring its automotive business.